SG11202104295UA - Gene therapy for neuronal ceroid lipofuscinoses - Google Patents
Gene therapy for neuronal ceroid lipofuscinosesInfo
- Publication number
- SG11202104295UA SG11202104295UA SG11202104295UA SG11202104295UA SG11202104295UA SG 11202104295U A SG11202104295U A SG 11202104295UA SG 11202104295U A SG11202104295U A SG 11202104295UA SG 11202104295U A SG11202104295U A SG 11202104295UA SG 11202104295U A SG11202104295U A SG 11202104295UA
- Authority
- SG
- Singapore
- Prior art keywords
- gene therapy
- neuronal ceroid
- ceroid lipofuscinoses
- lipofuscinoses
- neuronal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14001—Dipeptidyl-peptidase I (3.4.14.1), i.e. cathepsin-C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862767410P | 2018-11-14 | 2018-11-14 | |
US201962924060P | 2019-10-21 | 2019-10-21 | |
PCT/US2019/061206 WO2020102369A1 (en) | 2018-11-14 | 2019-11-13 | Gene therapy for neuronal ceroid lipofuscinoses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104295UA true SG11202104295UA (en) | 2021-06-29 |
Family
ID=70731911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104295UA SG11202104295UA (en) | 2018-11-14 | 2019-11-13 | Gene therapy for neuronal ceroid lipofuscinoses |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210393802A1 (ja) |
EP (1) | EP3880235A4 (ja) |
JP (1) | JP2022513034A (ja) |
KR (1) | KR20210092755A (ja) |
AU (1) | AU2019379141A1 (ja) |
BR (1) | BR112021009370A2 (ja) |
CA (1) | CA3117982A1 (ja) |
IL (1) | IL282808A (ja) |
MX (1) | MX2021005517A (ja) |
SG (1) | SG11202104295UA (ja) |
WO (1) | WO2020102369A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022546042A (ja) * | 2019-08-29 | 2022-11-02 | バイオマリン ファーマシューティカル インコーポレイテッド | 小児対象のcln2疾患を治療するための方法 |
CA3156984A1 (en) * | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
IL301643A (en) | 2020-10-07 | 2023-05-01 | Regenxbio Inc | Gene therapy for ocular manifestations of CLN2 disease |
MX2023006471A (es) * | 2020-12-18 | 2023-08-11 | Sangamo Therapeutics Inc | Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado. |
US20240091380A1 (en) * | 2021-02-01 | 2024-03-21 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
WO2023113806A1 (en) * | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
WO2022221193A1 (en) * | 2021-04-12 | 2022-10-20 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
CA3218350A1 (en) * | 2021-05-17 | 2022-11-24 | Sarepta Therapeutics, Inc. | Production of recombinant aav vectors for treating muscular dystrophy |
US20230293724A1 (en) * | 2022-03-14 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Lyophilized Formulations of AAV Drug Products |
WO2023196873A1 (en) * | 2022-04-06 | 2023-10-12 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration |
CN115869425A (zh) * | 2022-12-12 | 2023-03-31 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090122465A (ko) * | 2007-03-01 | 2009-11-30 | 어드벤스드 비젼 테라피스, 인코포레이티드 | 염증성 질환의 치료 |
US9849195B2 (en) * | 2011-03-31 | 2017-12-26 | University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
EP2797613B1 (en) * | 2011-10-27 | 2019-12-04 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
WO2015060722A1 (en) * | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
SG10201907399RA (en) * | 2015-02-10 | 2019-09-27 | Genzyme Corp | Enhanced delivery of viral particles to the striatum and cortex |
CN110121356A (zh) * | 2016-09-02 | 2019-08-13 | 星火治疗股份有限公司 | 治疗cns疾病的方法和载体 |
WO2018085688A1 (en) * | 2016-11-04 | 2018-05-11 | The Children's Hospital Of Philadelphia | Gene transfer compositions, methods and uses for treating neurodegenerative diseases |
WO2018209205A1 (en) * | 2017-05-11 | 2018-11-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for neuronal ceroid lipofuscinoses |
-
2019
- 2019-11-13 MX MX2021005517A patent/MX2021005517A/es unknown
- 2019-11-13 CA CA3117982A patent/CA3117982A1/en active Pending
- 2019-11-13 AU AU2019379141A patent/AU2019379141A1/en active Pending
- 2019-11-13 KR KR1020217017295A patent/KR20210092755A/ko unknown
- 2019-11-13 BR BR112021009370-2A patent/BR112021009370A2/pt unknown
- 2019-11-13 WO PCT/US2019/061206 patent/WO2020102369A1/en unknown
- 2019-11-13 JP JP2021526294A patent/JP2022513034A/ja active Pending
- 2019-11-13 SG SG11202104295UA patent/SG11202104295UA/en unknown
- 2019-11-13 EP EP19884046.4A patent/EP3880235A4/en active Pending
- 2019-11-13 US US17/292,750 patent/US20210393802A1/en active Pending
-
2021
- 2021-04-29 IL IL282808A patent/IL282808A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3880235A1 (en) | 2021-09-22 |
WO2020102369A1 (en) | 2020-05-22 |
CA3117982A1 (en) | 2020-05-22 |
MX2021005517A (es) | 2021-06-18 |
KR20210092755A (ko) | 2021-07-26 |
BR112021009370A2 (pt) | 2021-08-17 |
IL282808A (en) | 2021-06-30 |
US20210393802A1 (en) | 2021-12-23 |
JP2022513034A (ja) | 2022-02-07 |
EP3880235A4 (en) | 2022-08-10 |
AU2019379141A1 (en) | 2021-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282808A (en) | Gene therapy for neuronal ceroid lipofuscinosis | |
SG10201912401QA (en) | Gene therapy for neuronal ceroid lipofuscinoses | |
EP3468594A4 (en) | GENE THERAPY OF NEURONAL CEROID LIPOFUSCINOSIS | |
IL290149A (en) | Combined treatment for cancer | |
IL262211B1 (en) | Gene therapy for the treatment of type ii mucositis | |
HK1258518A1 (zh) | 用於眼病的基因療法 | |
EP3258965A4 (en) | Combination therapy for cancer treatment | |
LT3612237T (lt) | Genų terapija | |
IL279685A (en) | Gene therapy | |
IL282093A (en) | Combination therapy for cancer | |
ZA202100244B (en) | Combinatorial gene therapy | |
IL268946A (en) | Gene therapy for ocular disorders | |
GB201707212D0 (en) | Gene therapy for ciliopathies | |
GB201802326D0 (en) | Gene therapy | |
IL275613A (en) | Gene therapy for eosinophilic disorders | |
GB201817470D0 (en) | Gene therapy | |
IL304721A (en) | Gene therapy for neuronal ceroid lipofuscinoses | |
GB201701968D0 (en) | Gene therapy | |
EP3760209C0 (en) | GENE THERAPY SPECIFIC TO THE SITE OF AN ISCHEMIC INJURY | |
GB201820982D0 (en) | Gene Therapy | |
GB201811541D0 (en) | Gene therapy | |
GB201801511D0 (en) | Gene therapy | |
IL277696A (en) | Gene therapy for oxidative stress | |
IL263085A (en) | Garden healing | |
EP3706752A4 (en) | COMBINATORY THERAPY FOR ANTI-CANCER TREATMENT |